Regulation of B Cell Activation by PECAM-1: Implications for the Development of Autoimmune Disorders

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|10|2|155-161

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.10, Iss.2, 2004-01, pp. : 155-161

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders

By Kalled Susan L   Ambrose Christine   Hsu Yen-Ming  

Expert Opinion on Therapeutic Targets, Vol. 7, Iss. 1, 2003-02 ,pp. : 115-123

Informa Healthcare

Access to resources Recommend Favorite

Drug-Induced Liver Disorders: Implications for Drug Development and Regulation

By Kaplowitz N.  

Drug Safety, Vol. 24, Iss. 7, 2001-01 ,pp. : 483-490

Adis International

Access to resources Recommend Favorite

Regulation of B-Cell Activation by Complement Receptors CD21 and CD35

By  

Current Pharmaceutical Design, Vol. 9, Iss. 23, 2003-09 ,pp. : 1849-1860

Bentham Science Publishers

Access to resources Recommend Favorite

Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders

By Robak Tadeusz   Robak Ewa  

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 7, 2012-07 ,pp. : 921-947

Informa Healthcare

Access to resources Recommend Favorite

Recent progress in the development of selective S1P1 receptor agonists for the treatment of inflammatory and autoimmune disorders

By Buzard Daniel J   Thatte Jayant   Lerner Michael   Edwards Jeffrey   Jones Robert M  

Expert Opinion on Therapeutic Patents, Vol. 18, Iss. 10, 2008-10 ,pp. : 1141-1159

Informa Healthcare

Access to resources Recommend Favorite